Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results

BACKGROUND: Flu-like symptoms are common adverse events associated with interferon beta relapsing multiple sclerosis therapies. OBJECTIVES: To evaluate the incidence and severity of flu-like symptoms after transitioning from non-pegylated interferons to peginterferon beta-1a and assess flu-like symp...

Descripción completa

Detalles Bibliográficos
Autores principales: Naismith, Robert T, Hendin, Barry, Wray, Sibyl, Huang, DeRen, Gaudenzi, Fiorenza, Dong, Qunming, Sperling, Bjørn, Mann, Monica, Werneburg, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354308/
https://www.ncbi.nlm.nih.gov/pubmed/30729026
http://dx.doi.org/10.1177/2055217318822148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354308/
https://www.ncbi.nlm.nih.gov/pubmed/30729026
http://dx.doi.org/10.1177/2055217318822148

Ejemplares similares